Interleukin 10 extends the effectiveness of standard therapy during late sepsis with serum interleukin 6 levels predicting outcome

Shock

Volumn 23, Issue 6, 2005, Pages 521-526

  Manley, Mollie O ^a   O'Riordan, Mary Ann ^a   Levine, Alan D ^a   Latifi, Samir Q ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Cecal ligation and puncture; Cytokines; Lymphocytes; Peritonitis; Septic shock

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CECUM; CELL STIMULATION; CYTOKINE PRODUCTION; DRUG EFFICACY; HOSPITALIZATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LENGTH OF STAY; LIGATION; MOUSE; NECROSIS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PUNCTURE; SEPSIS; SPLEEN CELL; SURVIVAL; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SEPSIS; SHOCK, SEPTIC; SPLEEN; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME;

EID: 18744377694     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000161386.23817.7f     Document Type: Article

References (36)

1. Riedemann NC, Guo RF, Ward PA: Novel strategies for the treatment of sepsis. Nat Med 9:517-524, 2003.
2. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348:138-150, 2003.
3. Riche FC, Cholley BP, Panis YH, Laisne MJ, Briard CG, Graulet AM, Gueris JL, Valleur PD: Inflammatory cytokine response in patients with septic shock secondary to generalized peritonitis. Crit Care Med 28:433-437, 2000.
4. Heidecke CD, Hensler T, Weighardt H, Zantl N, Wagner H, Siewert JR, Holzmann B: Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg 178:288-292, 1999.
5. Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH: Polymicrobial sepsis but not low dose endotoxin infusion causes decreased splenocyte IL-2/IFN-γ release while increasing IL-4/IL-10 production. J Surg Res 56:579-585, 1994.
6. Song GY, Chung C-S, Chaudry IH, Ayala A: What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant? Surgery 126:378-383, 1999.
7. Kalechman Y, Gafter U, Gal R, Rushkin G, Yan D, Albeck M, Sredni B: Anti-IL-10 therapeutic strategy using the immunomodulator AS101 in protecting mice from sepsis-induced death: dependence on timing of immunomodulating intervention. J Immunol 169:384-392, 2002.
8. Baker CC, Chaudry IH, Gaines HO, Baue AE: Evaluations of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94:331-335, 1983.
9. Latifi SQ, O'Riordan MA, Levine AD: Interleukin-10 controls the onset of irreversible shock. Infect Immun 70:4441-4446, 2002.
10. Moore KW, Malefyt RW, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765, 2001.
11. Friedman G, Jankowski S, Marchant A, Goldman M, Kahn RJ, Vincent JL: Blood interleukin 10 levels parallel the severity of septic shock. J Crit Care 12:183-187, 1997.
12. van der Poll T, de Waal Malefyt R, Coyle SM, Lowry SF: Anti-inflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 175:118-122, 1997.
13. Thompson-Snipes LA, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM: Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 172:1625-1631, 1991.
14. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J: Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 89:1890-1893, 1992.
15. Tilg H, van Montfrans C, van den Ende A, Kaser A, van Deventer SJH, Schreiber S, Gregor M, Ludwiczek O, Rutgeerts P, Gasche C, Koningsberger JC, Abreu L, Kuhn I, Cohard M, LeBeaut A, Grint P, Weiss G: Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ. Gut 50:191-195, 2002.
16. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJH, van der Poll T: Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 165:2783-2789, 2000.
17. Latifi SQ, O'Riordan M, Levine AD, Stallion A: Persistent elevation of serum interleukin-6 in intra-abdominal sepsis identifies those with prolonged length of stay. J Pediatr Surg 39:1548-1552, 2004.
18. Thijs LG, Hack CE: Time course of cytokine levels in sepsis. Intensive Care Med 21:S258-S263, 1995.
19. Ebong S, Call D, Nemzek J, Bolgos G, Newcomb D, Remick D: Immunopathologic alterations in murine models of sepsis of increasing severity. Infect Immun 67:6603-6610, 1999.
20. Papaioannou VE, Fox JG: Efficacy of tribromoethanol anesthesia in mice. Lab Anim Sci 43:189-192, 1993.
21. Nemzek JA, Xiao HY, Minard AE, Bolgos GL, Remick DG: Humane endpoints in shock research. Shock 21:17-25, 2004.
22. Stallion A, Kou TD, Latifi SQ, Miller KA, Dahms BB, Dudgeon DL, Levine AD: Ischemia/reperfusion: a clinically relevant model of intestinal injury yielding systemic inflammation. J Pediatr Surg 40:470-477, 2005.
23. Kato T, Murata A, Ishida H, Toda H, Tanaka N, Hayashida H, Monden M, Matsuura N: Interleukin 10 reduces mortality from severe peritonitis in mice. Antimicrob Agents Chemother 39:1336-1340, 1995.
24. Holzheimer RG, Dralle H: Paradigm change in 30 years peritonitis treatment: a review on source control. Eur J Med Res 6:161-168, 2001.
25. Christou NV, Barie PS, Dellinger EP, Waymack JP, Stone HH: Surgical infection society intra-abdominal infection study: prospective evaluation of management techniques and outcome. Arch Surg 128:193-199, 1993.
26. Koperna T, Schulz F: Relaparotomy in peritonitis: prognosis and treatment of patients with persisting intraabdominal infection. World J Surg 24:32-37, 2000.
27. Lundblad R, Giercksky K-E: Effect of volume support, antibiotic therapy, and monoclonal antiendotoxin antibodies on mortality rate and blood concentrations of endothelin and other mediators in fulminant intra-abdominal sepsis in rats. Crit Care Med 23:1382-1390, 1995.
28. Wilson MA, Chou MC, Spain DA, Downard PJ, Qian Q, Cheadle WG, Garrison N: Fluid resuscitation attenuates early cytokine mRNA expression after peritonitis. J Trauma 41:622-627, 1996.
29. van der Poll T, Marchant A, Buurman WA, Berman L, Keogh CV, Lazarus DD, Nguyen L, Goldman M, Moldawer LL, Lowry SF: Endogenous IL-10 protects mice from death during septic peritonitis. J Immunol 155:5397-5401, 1995.
30. Sewnath ME, Olszyna DP, Birjmohun R, ten Kate FJ, Gouma DJ, van der Poll T: IL-10 deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J Immunol 166:6323-6331, 2001.
31. Docke W-D, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk H-D, Kox W: Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 3:678-681, 1997.
32. Fumeaux T, Pugin J: Role of IL-10 in the intracellular sequestration of HLA-DR in monocytes during septic shock. Am J Respir Crit Care Med 166:1475-1482, 2002.
33. Song GY, Chung CS, Chaudry IH, Ayala A: MAPK p38 antagonism as a novel method of inhibiting lymphoid immune suppression in polymicrobial sepsis. Am J Physiol Cell Physiol 281:C662-C669, 2001.
34. Himmelrich H, Launois P, Maillard I, Biedermann T, Tacchini-Cottier F, Locksley RM, Rocken M, Louis JA: In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is nscessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol 164:4819-4825, 2000.
35. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA: Six at six: interleukin 6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467, 2002.
36. Tumbull IR, Javadi P, Buchman TG, Hotchkiss RS, Karl IE, Coopersmith CM: Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 21:121-125, 2004.